Clinical Trial Update: Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluated adding Lapaquistat Acetate to standard lipid-lowering therapy for lowering cholesterol in Homozygous familial hypercholesterolemia; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Lapaquistat Acetate (lapaquistat acetate)

Snippet

Sponsor: Takeda | Conditions: Hypercholesterolemia | Phase 3 | Status: TERMINATED